Abstract

A compound of Formula (I): A compound of Formula (I): A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC═OR6, (C═O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/415 - 1,2-Diazoles
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C07C 69/90 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
• C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 317/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07H 15/22 - Cyclohexane rings, substituted by nitrogen atoms
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

A salt of a neuroceutical and of an acid, wherein the neuroceutical is a substituted benzodiazepine, a substituted benzothiazepine, a substituted pyridopyrimidines or a substituted amino-cyclohexaneacetic acid; and the acid is benzoic acid, nicotinic acid, pantothenic acid and tannic acid. The molar ratio of the neuroceutical and the acid in the salt ranges from about 6:1 to about 1:5. Also disclosed herein are compositions comprising the neuroceutical salt and therapeutic uses thereof for treating a central nervous system (CNS) disorder or a metabolic disorder associated with the CNS disorder.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Novel co-crystal and eutectic crystal of kojic acid and a co-former that are excellent in physical properties are provided. In one aspect, novel co-crystals of kojic acid and a co-former that is maltol or ethyl maltol are provided. In another aspect, novel crystal of a eutectic mixture of kojic acid and a co-former that is selected from the group consisting of, maltol, ethyl maltol, methyl paraben and propyl gallate are provided. Methods for producing the novel co-crystal or eutectic crystal are also described. The novel co-crystals and eutectic crystals may be included in a pharmaceutical composition, a health food product or a medical food product for the treatment and/or prophylaxis of a neuropsychiatric disorder.

IPC Classes  ?

• C07D 309/40 - Oxygen atoms attached in positions 3 and 4, e.g. maltol
• C07C 69/78 - Benzoic acid esters

Abstract

A compound of Formula (I): 6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).

IPC Classes  ?

• C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/415 - 1,2-Diazoles
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• C07C 69/90 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 317/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07H 15/22 - Cyclohexane rings, substituted by nitrogen atoms
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 38/21 - Interferons
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/499 - Spiro-condensed pyrazines or piperazines
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/4245 - Oxadiazoles
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A solid dosage form comprises an inner core containing a cycloserine compound and an outer layer attached to the inner core. The dosage form can be enteric tablet or transdermal patch, suitable for treating a neuropsychiatric disorder or tuberculosis.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/24 - Antidepressants
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

Provided herein is salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I), wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided herein are methods for treating and/or reducing the risk of a neuropsychiatric disorder and/or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).

IPC Classes  ?

• C07C 63/08 - Salts thereof
• C07D 213/55 - AcidsEsters
• C07C 57/10 - Sorbic acid
• C07C 57/44 - Cinnamic acid

Abstract

A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/7024 - Esters of saccharides
• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• A61K 36/49 - Fagaceae (Beech family), e.g. oak or chestnut
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 38/21 - Interferons
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/499 - Spiro-condensed pyrazines or piperazines
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/4245 - Oxadiazoles
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

Provided herein are potent compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, pain, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein. (I) Provided herein are potent compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, pain, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein. (I)

IPC Classes  ?

• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• A61P 3/06 - Antihyperlipidemics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurogenerative disorders).

IPC Classes  ?

• C07D 213/80 - AcidsEsters in position 3
• C07C 63/08 - Salts thereof
• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
• A61P 35/00 - Antineoplastic agents
• C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• C07C 57/10 - Sorbic acid

Abstract

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

IPC Classes  ?

• A61K 31/7024 - Esters of saccharides
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/06 - Antiasthmatics
• C07H 1/08 - SeparationPurification from natural products
• C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 36/49 - Fagaceae (Beech family), e.g. oak or chestnut
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 25/16 - Anti-Parkinson drugs
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to compounds of Formula (I): C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Novel co-crystal and eutectic crystal of kojic acid and a co-former that are excellent in physical properties are provided. In one aspect, novel co-crystals of kojic acid and a co-former that is maltol or ethyl maltol are provided. In another aspect, novel crystal of a eutectic mixture of kojic acid and a co-former that is selected from the group consisting of, maltol, ethyl maltol, methyl paraben and propyl gallate are provided. Methods for producing the novel co-crystal or eutectic crystal are also described. The novel co-crystals and eutectic crystals may be included in a pharmaceutical composition, a health food product or a medical food product for the treatment and/or prophylaxis of a neuropsychiatric disorder.

IPC Classes  ?

• C07D 309/40 - Oxygen atoms attached in positions 3 and 4, e.g. maltol

Goods & Services

Acids for pharmaceutical purposes, namely, aromatic acids for the treatment of viral infection; antibiotics; viral antibiotics; cachets for pharmaceutical purposes, namely, cachets filled with aromatic acids for the treatment of viral infection; cachou for pharmaceutical purposes, namely, cachou filled with aromatic acids for the treatment of viral infection; candy, medicated; candy for medical purposes; capsules filled with aromatic acids for the treatment of viral infection; chemical preparations for pharmaceutical purposes for the treatment of viral infection; chemical preparations for medical purposes for the treatment of viral infection; chemical preparations for veterinary purposes for the treatment of viral infection; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for the treatment of viral infection; chewing gum for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic injection and dietetic infusion adapted for medical use; drugs for medical purposes for the treatment of viral infection; flour for pharmaceutical purposes; meal for pharmaceutical purposes; freeze-dried food adapted for medical purposes; lyophilized food adapted for medical purposes; germicides; gum for medical purposes for the treatment of viral infection; homogenized food adapted for medical purposes; medicated animal feed; medicated dentifrices; medicinal infusions for the treatment of viral infection; medicines for human purposes for treatment of viral infection; medicines for veterinary purposes for treatment of viral infection; preparations being cultures of microorganisms for medical or veterinary use; nervines; nutraceutical preparations for treatment of viral infection; nutritional supplements; ointments for treatment of viral infection; cough pastilles for pharmaceutical purposes; cough lozenges for pharmaceutical purposes; pectin for pharmaceutical purposes for treatment of viral infection; pharmaceutical preparations for treatment of viral infection; pharmaceuticals for treatment of viral infection; poultices; pre-filled syringes filled with aromatic acids for the treatment of viral infection; aromatic acid salts for the treatment of viral infection; sedatives; tranquillizers; suppositories for treatment of viral infection; syrups for pharmaceutical purposes for treatment of viral infection; medicated tonics for the treatment of viral infection; inhalation devices, namely, inhalers filled with aromatic acids for the treatment of viral infection; drugs for pulmonary administration for the treatment of viral infection

Abstract

Formulations comprising cycloserine compounds and one or more enteric materials in a solid dosage form, and uses thereof for treating and/or reducing the risk of a neuropsychiatric disorder or tuberculosis.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/24 - Antidepressants
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

Provided herein are compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein.

IPC Classes  ?

• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• A61P 3/06 - Antihyperlipidemics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I): wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided in the present invention are methods for treating and/or reducing the risk of a neuropsychiatric disorder and/or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 59/255 - Tartaric acid
• C07C 57/15 - Fumaric acid
• C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid

Abstract

The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurodegenerative disorders).

IPC Classes  ?

• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
• C07C 63/08 - Salts thereof
• A61P 35/00 - Antineoplastic agents
• C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• C07D 213/80 - AcidsEsters in position 3
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/22 - Anxiolytics
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• C07C 57/10 - Sorbic acid

Abstract

Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).

IPC Classes  ?

• C07C 63/08 - Salts thereof
• C07D 213/55 - AcidsEsters
• C07C 57/10 - Sorbic acid
• C07C 57/44 - Cinnamic acid

Abstract

The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): 3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/12 - Ketones
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A23L 33/16 - Inorganic salts, minerals or trace elements
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The present invention relates to compounds of Formula (I): C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): 3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/16 - Inorganic salts, minerals or trace elements
• A61K 31/12 - Ketones
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).

IPC Classes  ?

• A23L 33/16 - Inorganic salts, minerals or trace elements
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
• C07C 51/43 - SeparationPurificationStabilisationUse of additives by change of the physical state, e.g. crystallisation
• C07C 63/08 - Salts thereof
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid

Abstract

Methods for treating central nervous system (CNS) disorders or attenuating pain with a lithium benzoate compound.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/00 - Drugs for disorders of the nervous system

Goods & Services

Syrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment and prevention of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Transdermal patches for use in the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Natural dietary supplements for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes

Abstract

The present invention relates to a pharmaceutical composition comprising a sodium benzoate compound and clozapine; and a method for preventing, treating and/or reducing the risk of a neuropsychiatric disorder by administering such pharmaceutical composition.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Sodium salts for medical purposes

Abstract

The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 59/255 - Tartaric acid
• C07C 57/15 - Fumaric acid
• C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid

Abstract

The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 59/255 - Tartaric acid
• C07C 57/15 - Fumaric acid
• C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; chemical reagents for medical or veterinary purposes, excluding reagents for use in development of skin care products or cosmetics; antibacterial substances for medical purposes, excluding antibacterial substances for use in skin care products or cosmetics; amino acid preparations for medical purposes, excluding amino acid preparations for use in skin care products or cosmetics; amino acids for medical or veterinary purposes, excluding amino acids for use in skin care products or cosmetics; amino acids for medical purposes, excluding amino acids for use in skin care products or cosmetics

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Antibacterial substances for medical purposes; Amino acid preparations for medical purposes; Amino acids for medical or veterinary purposes; Amino acids for medical purposes

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Antibacterial substances for medical purposes; Amino acid preparations for medical purposes; Amino acids for medical or veterinary purposes; Amino acids for medical purposes

Abstract

Methods for preparing tannic acid-containing compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions), particularly those having enriched tannic acid populations with superior potency, purity and safety profile. Also provide herein are the tannic acid-containing compositions for use in inhibiting D-amino acid oxidase and/or for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

IPC Classes  ?

• A61K 31/7024 - Esters of saccharides

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Syrups for pharmaceutical purposes for the treatment of ADHD; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Adjuvants for medical purposes; Animal feed additive for use as a nutritional supplement for medical purposes; Amino acid preparations for medical purposes; Amino acids for medical or veterinary purposes; Amino acids for medical purposes; Beverages containing amino acid for use as a nutritional supplement; Liquid nutritional supplement; Amino acids for nutritional purposes; Dietary and nutritional supplements; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Powdered nutritional supplement drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplements consisting primarily of amino acid; Nutritional supplement shakes; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements in capsule form for dogs; Nutritional supplements; Nutritionally fortified water for medical purposes; Nutritionally fortified beverages for medical purposes; Vitamin fortified beverages for medical purposes; Vitamin enriched chewing gum for medical purposes; Soy protein for use as a nutritional supplement in various powdered and ready-to-drink beverages; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Powdered nutritional supplement drink mix containing amino acid; Nutritional supplements for cats, dogs; Nutraceuticals for use as a dietary supplement for depressed mood; Nutraceuticals for the treatment of CNS disorders; Nutraceuticals for use as a dietary supplement

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Sodium salts for medical purposes

Goods & Services

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Phenol for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Syrups for pharmaceutical purposes for the treatment of dementia; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Plant extracts for pharmaceutical purposes; Pharmaceutical preparations for treating sunburn; Chemical reagents for medical or veterinary purposes; Adjuvants for medical purposes; Animal feed additive for use as a nutritional supplement for medical purposes; Medicinal herbal extracts for medical purposes; Antibacterial substances for medical purposes; Transdermal patches featuring medication for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plant; Herbal extracts for medical purposes; Phytotherapy preparations for medical purposes; Appetite suppressants for medical purposes; Beverages containing tannic acid for use as a nutritional supplement; Liquid nutritional supplement; Dietary and nutritional supplements; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Powdered nutritional supplement drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplements consisting primarily of tannic acid; Dietary and nutritional supplements used for weight loss; Nutritional supplement shakes; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements in capsule form for dogs; Nutritional supplements; Nutritional supplement for eliminating toxins from the body; Nutritionally fortified water for medical purposes; Nutritionally fortified beverages for medical purposes; Vitamin fortified beverages for medical purposes; Vitamin enriched chewing gum for medical purposes; Soy protein for use as a nutritional supplement in various powdered and ready-to-drink beverages; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Powdered nutritional supplement drink mix containing tannic acid; Nutritional supplements for cats, dogs; Nutraceuticals for use as a dietary supplement for cognitive impairment; Nutraceuticals for the treatment of CNS disorders; Nutraceuticals for use as a dietary supplement

Abstract

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07H 1/08 - SeparationPurification from natural products
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 36/22 - Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 36/49 - Fagaceae (Beech family), e.g. oak or chestnut
• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/7024 - Esters of saccharides
• C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 59/255 - Tartaric acid
• C07C 57/15 - Fumaric acid
• C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid